NDAORALCAPSULE
Approved
Jul 1974
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
3/8 — Basic
TIGAN (trimethobenzamide hydrochloride) by Pfizer is 12. First approved in 1974.
Drug data last refreshed 14h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TIGAN (trimethobenzamide HCl) is a small-molecule antiemetic that acts on the chemoreceptor trigger zone in the medulla to prevent nausea and vomiting. The exact mechanism remains incompletely characterized, but it selectively inhibits emetic responses from certain triggers while showing limited efficacy against others. It is indicated for the prevention and treatment of nausea and vomiting across multiple clinical contexts.
LOE Approaching
With LOE approaching and competitive pressure at 30%, the TIGAN brand team is likely in stabilization or transition mode, with reduced headcount and focus shifting toward managed care and generic transition planning.
Mechanism of Action
12.1 Mechanism of Action The mechanism of action of trimethobenzamide as determined in animals is obscure, but may involve the chemoreceptor trigger zone (CTZ), an area in the medulla oblongata through which emetic impulses are conveyed to the vomiting center; direct impulses to the vomiting center…
Worked on TIGAN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.